Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      • Home
      • Farhat Nasim

      Articles By : Farhat Nasim

      Drugs and Magic Remedies act to cover online, electronic media; have higher penalties

      Drugs and Magic Remedies act to cover online, electronic media; have higher penalties

      Farhat Nasim19 Jan 2020 11:15 AM IST
      New Delhi: In a stringent view to regulate the menace of misleading advertisements opted tactfully by many companies to enhance the sale of their...
      CDSCO declares 450 FDCs as rational, issues directions for manufacturers

      CDSCO declares 450 FDCs as rational, issues directions for manufacturers

      Farhat Nasim15 Jan 2020 1:27 PM IST
      New Delhi: Apex drug regulator, Central Drugs Standard Control Organization (CDSCO) has recently declared 450 more Fixed-Dose Combination (FDC)...
      Former BDM, others arrested for stealing data from pharma firm

      Former BDM, others arrested for stealing data from pharma firm

      Farhat Nasim15 Jan 2020 10:30 AM IST
      Investigations revealed that the prime accused, who was a Business Development Manager in the pharma company was fired on the charge of malpractices.
      Drug Alert: CDSCO declares 49 drug samples as Not of Standard Quality; Details

      Drug Alert: CDSCO declares 49 drug samples as Not of Standard Quality; Details

      Farhat Nasim14 Jan 2020 2:32 PM IST
      New Delhi: In its latest drug safety alert, the apex drug regulatory body, Central Drugs Standard Control Organization (CDSCO) recently flagged 49...
      Lupin Tarapur facility cautioned by USFDA post inspection

      Lupin Tarapur facility cautioned by USFDA post inspection

      Farhat Nasim14 Jan 2020 1:11 PM IST
      "The company has received a communication from the US FDA classifying the inspection conducted at its Tarapur manufacturing (API) facility between...
      Alembic Pharma gets USFDA nod for depression drug Vilazodone Hydrochloride tablets

      Alembic Pharma gets USFDA nod for depression drug Vilazodone Hydrochloride tablets

      Farhat Nasim14 Jan 2020 12:52 PM IST
      "The approved ANDA (Vilazodone Hydrochloride tablets) is therapeutically equivalent to the reference listed drug product (RLD), Viibryd tablets, 10...
      Biogen to buy Alzheimers, Parkinsons treatment from Pfizer for USD 75 million

      Biogen to buy Alzheimers, Parkinsons treatment from Pfizer for USD 75 million

      Farhat Nasim14 Jan 2020 12:40 PM IST
      Under the deal with Biogen, Pfizer will get $75 million upfront and will be eligible for $635 million in potential milestone payments.New Delhi:...
      DoP rejects Geltec plea to review price of Ibuprofen Capsule fixed by NPPA

      DoP rejects Geltec plea to review price of Ibuprofen Capsule fixed by NPPA

      Farhat Nasim13 Jan 2020 3:44 PM IST
      New Delhi: In a major setback to drugmaker Geltec Private Limited, the Department of Pharmaceuticals (DoP) has junked its review petition against the...
      Granules India recalls over 2.3 cr ranitidine tablets from US market

      Granules India recalls over 2.3 cr ranitidine tablets from US market

      Farhat Nasim13 Jan 2020 11:59 AM IST
      New Delhi: Drug firm Granules India is recalling over 2.3 crore ranitidine tablets, used to treat ulcers of the stomach and intestines, from the US...
      Sorrento surges on a near 1 billion dollar takeout offer

      Sorrento surges on a near 1 billion dollar takeout offer

      Farhat Nasim13 Jan 2020 9:02 AM IST
      US: Sorrento Therapeutics Inc said on Friday it had received a proposal from a private equity fund interested in acquiring a majority or all of its...
      No Relief: DOP rejects review petition by CIPLA challenging NPPA price fixation

      No Relief: DOP rejects review petition by CIPLA challenging NPPA price fixation

      Farhat Nasim12 Jan 2020 10:00 AM IST
      New Delhi: Holding that drugmaker, Cipla did not comply with the mandatory implementation of the retail price of the formulation before filing the...
      Biosimilars global market expected to grow to USD 23.6 billion by 2023: ICRA

      Biosimilars global market expected to grow to USD 23.6 billion by 2023: ICRA

      Farhat Nasim12 Jan 2020 9:45 AM IST
      The biosimilars global market, which stood at USD 5.9 billion in the calendar year 2018, is expected to grow to USD 23.6 billion by 2023, backed by...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok